Bevacizumab combined with re-irradiation in recurrent glioblastoma
BackgroundGlioblastoma is characterized by rich vasculature and abnormal vascular structure and function. Currently, there is no standard treatment for recurrent glioblastoma (rGBM). Bevacizumab (BEV) has established role of inhibiting neovascularization, alleviating hypoxia in the tumor area and ac...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2022-08-01
|
| Серии: | Frontiers in Oncology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fonc.2022.961014/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|